Glen Eagle Advisors’s Heron Therapeutics HRTX Stock Holding History

Glen Eagle Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-100	Closed	-$2.12K	–	1011
2020 Q4	$2.12K	Hold	100	–	–	﹤0.01%	847
2020 Q3	$1.48K	Hold	100	–	–	﹤0.01%	817
2020 Q2	$1.47K	Buy	+100	New	+$1.64K	﹤0.01%	784

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Glen Eagle Advisors's HRTX Position: Q1 2021 in Review

Glen Eagle Advisors sold out of Heron Therapeutics (HRTX) in Q1 2021, closing a stake of 100 shares — an estimated $2.12K sold.

Glen Eagle Advisors first reported a position in HRTX in Q2 2020 and held it in 3 quarters. The position peaked at $2.12K in Q4 2020. 193 funds tracked by Wall St. Rank hold HRTX as of Q1 2021.

Glen Eagle Advisors reported no remaining Heron Therapeutics position as of Q1 2021 after selling out during the quarter.
Glen Eagle Advisors sold 100 Heron Therapeutics shares in Q1 2021, an estimated $2.12K.
Glen Eagle Advisors first reported a position in Heron Therapeutics in Q2 2020 and held it in 3 quarters.
Glen Eagle Advisors's Heron Therapeutics position peaked at $2.12K in Q4 2020.
193 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2021.

Based on Glen Eagle Advisors's 13F filing for Q1 2021, filed 13 Aug 2024.